Suzhou Immunofoco Biotechnology Co., Ltd

This study tests a new drug called IMC002 in adults with advanced stomach cancer that has a specific marker (CLDN18.2) and has not responded to at least two prior treatments. About 150 participants will receive either IMC002 or a standard treatment chosen by their doctor. The goa…

This early-phase study tests a new treatment called IMV102 in 30 people with multiple myeloma that has returned or not responded to at least three prior therapies. Participants receive a single infusion of their own modified immune cells. The main goal is to check safety, and res…

This study tests a new drug, IMV101, in 30 adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer. The main goals are to check the drug's safety and find the best dose. Researchers will also see if the drug can shrink tumors or slow the cancer's gr…